Ivermectin B1b

• CAT Number: R034932
• CAS Number: 70209-81-3
• Molecular Formula: C47H72O14
• Molecular Weight: 861.08
• Purity: ≥95%
• Synonyms: 5-O-Demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a; Spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2’-[2H]pyran] Avermectin A1a Deriv.; 22,23-Dihydroavermectin B1b
• Target: Parasite
• Storage: -20°C
• IUPAC Name: (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethyl-6'-propan-2-ylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
• InChI: InChI=1S/C47H72O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1
• InChIKey: VARHUCVRRNANBD-PVVXTEPVSA-N
• SMILES: C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C

Ivermectin B1a（Cat No.:R034932）is a major component of ivermectin, a broad-spectrum antiparasitic agent derived from Streptomyces avermitilis. It is highly effective against a wide range of parasites, including nematodes, mites, and lice, in both humans and animals. Ivermectin B1a works by binding to glutamate-gated chloride ion channels in the parasites’ nerve and muscle cells, causing paralysis and death. It is widely used for treating conditions such as onchocerciasis, lymphatic filariasis, and scabies in humans, as well as parasitic infections in livestock and pets. Its potency and safety profile make it indispensable in global parasitic disease control.

Reference

1.Campbell, W. C., et al. "Ivermectin: a potent new antiparasitic agent." Science 221.4613 (1983): 823-828.
2.Wolstenholme, A. J., and A. T. Rogers. "Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics." Parasitology 131.S1 (2005): S85.
3.Arena, Joseph P., et al. "The mechanism of action of avermectins in Caenorhabditis elegans: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity." The Journal of parasitology (1995): 286-294.
4.Caly, Leon, et al. "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro." Antiviral research 178 (2020): 104787.